GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (FRA:D4S) » Definitions » EV-to-Revenue
中文

Daiichinkyo Co (FRA:D4S) EV-to-Revenue

: 4.85 (As of Today)
View and export this data going back to 2005. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Daiichinkyo Co's enterprise value is €47,615 Mil. Daiichinkyo Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €9,824 Mil. Therefore, Daiichinkyo Co's EV-to-Revenue for today is 4.85.

The historical rank and industry rank for Daiichinkyo Co's EV-to-Revenue or its related term are showing as below:

FRA:D4S' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.99   Med: 2.4   Max: 7.39
Current: 5.21

During the past 13 years, the highest EV-to-Revenue of Daiichinkyo Co was 7.39. The lowest was 0.99. And the median was 2.40.

FRA:D4S's EV-to-Revenue is ranked worse than
77.51% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.3 vs FRA:D4S: 5.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-24), Daiichinkyo Co's stock price is €27.80. Daiichinkyo Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €5.12. Therefore, Daiichinkyo Co's PS Ratio for today is 5.43.


Daiichinkyo Co EV-to-Revenue Historical Data

The historical data trend for Daiichinkyo Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.23 5.75 4.27 6.70

Daiichinkyo Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.34 6.70 6.03 5.24 4.22

Competitive Comparison

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's EV-to-Revenue falls into.



Daiichinkyo Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Daiichinkyo Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=47614.760/9824.394
=4.85

Daiichinkyo Co's current Enterprise Value is €47,615 Mil.
Daiichinkyo Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €9,824 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (FRA:D4S) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Daiichinkyo Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=27.80/5.121
=5.43

Daiichinkyo Co's share price for today is €27.80.
Daiichinkyo Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.12.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (FRA:D4S) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (FRA:D4S) Headlines

No Headlines